Martin Shkreli and his newest adversary just had an awkward public exchange
After the tense session ended, Business Insider asked Miller to fact-check Shkreli's claim about the email "begging" for business. Here's what he had to say:
"We have a company called UBC, and they were doing the patient assistance program for the prior owner of Daraprim. Obviously with the change of ownership there was a renegotiation of the contract. We were more than happy to support a patient assistance program when the drug was priced at $13.50. When the price of the drug went up to $750, obviously we had to take a different approach."
"We definitely were supporting the drug in the past. We definitely have no desire to support the drug in the future, but we will not abandon the patients in the interim."
The news of Express Scripts partnership with compounding pharmaceutical company Imprimis to provide their compounded version of pyrimethamine, the active part of Daraprim. Imprimis combines pyrimethamine with leucovorin, a form of B-vitamin folic acid that's recommended to treat toxoplasmosis by the US Centers for Disease Control and Prevention.
But, this partnership with Imprimis is specific to the toxoplasmosis condition, and the small population of patients who actually need to take Daraprim.
"This is really we think this a unique situation where this could be a solution," he said. "We don't look at this as becoming a new standard."